Drug firm Natco Pharma today said it has received establishment inspection report (EIR) from the US health regulator for its Kothur facility in Telangana after successful completion of inspection.
Natco Pharma announces successful EIR from the US Food and Drug Administration (USFDA) for the inspection conducted at its drug manufacturing facility in Kothur village in Mahabubnagar district during January 16-24, 2017, the company said in a BSE filing today.
"The Kothur facility predominantly caters to regulated international markets, including USA," it added.
EIR is given to an establishment after completion of inspection by the USFDA.
The Natco Pharma stock was trading 1.05 per cent higher at Rs 1,009 on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
